Outset Medical, Inc. (NASDAQ:OM) COO Martin Vazquez Sells 22,500 Shares

Outset Medical, Inc. (NASDAQ:OM) COO Martin Vazquez sold 22,500 shares of Outset Medical stock in a transaction that occurred on Thursday, April 1st. The stock was sold at an average price of $55.05, for a total transaction of $1,238,625.00. Following the completion of the transaction, the chief operating officer now directly owns 21,971 shares in the company, valued at approximately $1,209,503.55. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of NASDAQ:OM opened at $54.06 on Thursday. The firm has a 50 day simple moving average of $51.23 and a 200 day simple moving average of $53.81. Outset Medical, Inc. has a 52 week low of $42.50 and a 52 week high of $66.96. The company has a debt-to-equity ratio of 0.08, a quick ratio of 10.77 and a current ratio of 11.13.

Outset Medical (NASDAQ:OM) last announced its earnings results on Monday, March 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.09). The business had revenue of $17.25 million for the quarter, compared to the consensus estimate of $13.79 million. As a group, analysts expect that Outset Medical, Inc. will post -9.61 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of OM. Vestcor Inc acquired a new position in Outset Medical in the 3rd quarter valued at approximately $50,000. State of Tennessee Treasury Department purchased a new position in shares of Outset Medical during the 3rd quarter valued at $82,000. Citigroup Inc. acquired a new position in shares of Outset Medical in the fourth quarter worth $107,000. Strs Ohio purchased a new stake in shares of Outset Medical during the fourth quarter worth $136,000. Finally, Paloma Partners Management Co purchased a new stake in shares of Outset Medical during the fourth quarter worth $230,000. 84.63% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms recently commented on OM. Oppenheimer assumed coverage on shares of Outset Medical in a research note on Wednesday, December 16th. They set a “market perform” rating for the company. Morgan Stanley increased their price objective on Outset Medical from $52.00 to $58.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 16th. Finally, Zacks Investment Research cut Outset Medical from a “buy” rating to a “hold” rating in a report on Friday, April 2nd. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $56.80.

About Outset Medical

Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo, a dialysis machine that enables dialysis care in acute and chronic settings. The Tablo comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities.

See Also: What are momentum indicators and what do they show?

Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.